HY-07121 / Huiyu Pharma - LARVOL DELTA

HY07121, a new generation of immune oncology therapeutics overcoming tumor immune resistance (AACR 2025) - "In vivo, HY07121 exhibited dose-dependent tumor inhibition in both the human bladder cancer cell derived xenograft model and the immune-resistant human melanoma cell (A375) derived xenograft model, significantly outperforming the combination of Pembrolizumab and Tiragolumab. The in vitro and in vivo findings suggest that HY07121 is a novel, mechanism-driven therapeutic with the potential to enhance the efficacy of immunotherapy and address both primary and acquired resistance. The pharmacological and toxicological profiles strongly support the continued clinical development of HY07121."

Bladder Cancer • Genito-urinary Cancer • Melanoma • Oncology • Solid Tumor • CD8 • IFNG • IL15 • TIGIT

Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=258 | Recruiting | Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=258 | Not yet recruiting | Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

Metastases • New P1/2 trial • Oncology • Solid Tumor

Huiyu Pharmaceutical’s PD-1/TIGIT/IL-15 triple antibody was approved for clinical trials (bydrug.pharmcube.com) - "On September 21, Huiyu Pharmaceuticals announced that its Class 1 new drug, HY07121, a triple-target antibody fusion protein for injection targeting PD-1/TIGIT/IL-15, has obtained implicit approval for clinical trials and is intended for use in patients with advanced solid tumors."

New trial • Oncology • Solid Tumor